Inovio reports inducement grants under nasdaq listing rule 5635(c)(4)

Plymouth meeting, pa. , july 1, 2022 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help protect people from infectious diseases and treat people with cancer and hpv-associated diseases, today announced that in connection with the hiring of dr. michael john sumner as chief medical officer, announced on june 27, 2022, the compensation committee of inovio's board of directors approved equity grants to dr. sumner as inducement awards under inovio's 2022 inducement plan (the "inducement plan").
INO Ratings Summary
INO Quant Ranking